3PE6

Crystal Structure of a soluble form of human MGLL in complex with an inhibitor


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.35 Å
  • R-Value Free: 0.147 
  • R-Value Work: 0.114 
  • R-Value Observed: 0.115 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.2 of the entry. See complete history


Literature

Crystal structure of a soluble form of human monoglyceride lipase in complex with an inhibitor at 1.35 A resolution.

Schalk-Hihi, C.Schubert, C.Alexander, R.Bayoumy, S.Clemente, J.C.Deckman, I.DesJarlais, R.L.Dzordzorme, K.C.Flores, C.M.Grasberger, B.Kranz, J.K.Lewandowski, F.Liu, L.Ma, H.Maguire, D.Macielag, M.J.McDonnell, M.E.Mezzasalma Haarlander, T.Miller, R.Milligan, C.Reynolds, C.Kuo, L.C.

(2011) Protein Sci 20: 670-683

  • DOI: 10.1002/pro.596
  • Primary Citation of Related Structures:  
    3PE6

  • PubMed Abstract: 
  • A high-resolution structure of a ligand-bound, soluble form of human monoglyceride lipase (MGL) is presented. The structure highlights a novel conformation of the regulatory lid-domain present in the lipase family as well as the binding mode of a pharmaceutically relevant reversible inhibitor ...

    A high-resolution structure of a ligand-bound, soluble form of human monoglyceride lipase (MGL) is presented. The structure highlights a novel conformation of the regulatory lid-domain present in the lipase family as well as the binding mode of a pharmaceutically relevant reversible inhibitor. Analysis of the structure lacking the inhibitor indicates that the closed conformation can accommodate the native substrate 2-arachidonoyl glycerol. A model is proposed in which MGL undergoes conformational and electrostatic changes during the catalytic cycle ultimately resulting in its dissociation from the membrane upon completion of the cycle. In addition, the study outlines a successful approach to transform membrane associated proteins, which tend to aggregate upon purification, into a monomeric and soluble form.


    Organizational Affiliation

    Department of Structural Biology, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., Welsh and McKean Roads, Spring House, Pennsylvania 19477, USA. cschalkh@its.jnj.com



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Monoglyceride lipaseA303Homo sapiensMutation(s): 3 
Gene Names: MGLLhCG_40840
EC: 3.1.1.23
Membrane Entity: Yes 
UniProt & NIH Common Fund Data Resources
Find proteins for Q99685 (Homo sapiens)
Explore Q99685 
Go to UniProtKB:  Q99685
PHAROS:  Q99685
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
ZYH (Subject of Investigation/LOI)
Query on ZYH

Download Ideal Coordinates CCD File 
B [auth A](2-cyclohexyl-1,3-benzoxazol-6-yl){3-[4-(pyrimidin-2-yl)piperazin-1-yl]azetidin-1-yl}methanone
C25 H30 N6 O2
IABLYMUVWHQTGC-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.35 Å
  • R-Value Free: 0.147 
  • R-Value Work: 0.114 
  • R-Value Observed: 0.115 
  • Space Group: C 2 2 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 93.947α = 90
b = 128.145β = 90
c = 60.602γ = 90
Software Package:
Software NamePurpose
StructureStudiodata collection
PHASERphasing
PHENIXrefinement
HKL-2000data reduction
HKL-2000data scaling

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment  



Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2011-03-02
    Type: Initial release
  • Version 1.1: 2011-07-13
    Changes: Version format compliance
  • Version 1.2: 2013-06-19
    Changes: Database references